Literature DB >> 6612680

Effects of verapamil on platelet aggregation, ATP release and thromboxane generation.

J Mehta, P Mehta, N Ostrowski, F Crews.   

Abstract

We examined the effects of verapamil on platelet function. Verapamil (0.5 micrograms/ml) in this study inhibited platelet aggregation induced by threshold amounts of ADP, AA, and epinephrine. With higher concentrations of aggregating stimuli, verapamil caused a dose-dependent inhibition of aggregation. Verapamil reduced the extent of epinephrine-induced primary wave, but not that by ADP. Ristocetin-induced aggregation was not affected at any concentration of verapamil. Platelet ATP release induced by AA and ADP was also inhibited. In vitro platelet TXA2 generation was inhibited by verapamil in concentrations lower than those required for inhibition of aggregation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6612680     DOI: 10.1016/0049-3848(83)90181-0

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  10 in total

1.  Effects of the calmodulin antagonists fendiline and calmidazolium on aggregation, secretion of ATP, and internal calcium in washed human platelets.

Authors:  A Lückhoff; M Bohnert; R Busse
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-01       Impact factor: 3.000

2.  Retardation of development and progression of coronary atherosclerosis: a new indication for calcium antagonists?

Authors:  W Schneider; G Kober; P Roebruck; H Noack; M Alle; G Cieslinski; N Reifart; M Kaltenbach
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  Calcium antagonists and their mode of action: an historical overview.

Authors:  W G Nayler; J S Dillon
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

Review 4.  Calcium antagonists: whither now?

Authors:  W G Nayler
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

Review 5.  Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

6.  Effects of isradipine sustained release on platelet function and fibrinolysis in essential hypertensives with or without other risk factors.

Authors:  G Ranieri; V Filitti; A Andriani; M V Bonfantino; G Lamontanara; A Cavallo; M Milani; R De Cesaris
Journal:  Cardiovasc Drugs Ther       Date:  1996-05       Impact factor: 3.727

7.  Blockade of receptor-operated calcium channels by mibefradil (Ro 40-5967): effects on intracellular calcium and platelet aggregation.

Authors:  M Hahn; V A Tkachuk; V N Bochkov; I B Cheglakov; J P Clozel
Journal:  Cardiovasc Drugs Ther       Date:  1995-12       Impact factor: 3.727

8.  Oral nimodipine reduces prostaglandin and thromboxane production by arteries chronically exposed to a periarterial haematoma and the antifibrinolytic agent tranexamic acid.

Authors:  J D Pickard; V Walker; J Vile; S Perry; P J Smythe; R Hunt
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-06       Impact factor: 10.154

9.  Inhibition of human platelet functions by cyclandelate.

Authors:  W E van den Hoven; D W Hall
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 10.  Can the coronary atherosclerotic process be influenced by calcium antagonists?

Authors:  G Kober; W Schneider; G Cieslinski; M Kaltenbach
Journal:  Drugs       Date:  1992       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.